IP Library Granted Patent US 11,655,465
Granted Patent B1
US 11,655,465 · App. 16/866,439 · Granted May 23, 2023

Enzymes and systems for synthesizing DNA

Inventors: Paul F. Predki (Carlsbad, CA); Stefen Boehme (Encinitas, CA)
Assignee: IRIDIA, INC.
C12N9/90B01L3/508C12N15/74C12P19/34C12Y599/01002B01L2300/047
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,655,465
App. No.
16/866,439
Granted
May 23, 2023
Kind
B1
Abstract

The disclosure provides novel topoisomerases which exhibit weakened ability to form a covalent bond to the 5′-(C/T)CCTT-3′ recognition site in the presence of increased NaCl concentrations relative to wild-type, together with novel methods for synthesizing DNA in the 3′ to 5′ direction using the novel topoisomerase; and other compounds, compositions, methods and devices comprising or utilizing topoisomerases which exhibit reduced covalent bond formation to the 5′-(C/T)CCTT-3′ recognition site in the presence of increased NaCl concentrations, relative to wild-type.

Claims (12)

1. A method of synthesizing a DNA molecule using topoisomerase-mediated ligation, by adding single nucleotides or oligomers to a DNA strand in the 3′ to 5′ direction, comprising (i) reacting a DNA molecule with a M-Topoisomerase charged with the desired nucleotide or oligomer wherein the nucleotide or oligomer is blocked from further addition at the 5′ end, then (ii) deblocking the 5′ end of the DNA thus formed, and repeating steps (i) and (ii) until the desired nucleotide sequence is obtained, wherein the M-Topoisomerase is a topoisomerase comprising the following sequence:

SEQ ID NO: 3

RALFYKDGKLFTDNNFLNPVSDDNPAYEVLQHVKIPTHLTDVVVYEQTWEEALT RLIFVGSDSKGX 1 RX 2 X 3 FYGKMHVQNX 4 NAKRDRIFVRVYNVMKRINCFINKNIK KSSTDSNYQLAVFMLMETMFFIRFGKMKYLKENETVGLLTLKNKHIEISPDEIVIK FVGKDKVSHEFVVHKSNRLYKPLLKLTDDSSPEEFLFNKLSERKVYECIKQFGIRI KDLRTYGVNYTFLYNFWTNVKSISPLPSPKKLIALTIKQTAEVVGHTPSISKRAY MATTILEMVKDKNFLDVVSKTTFDEFLSIVVDHVKSSTDG

wherein at least two of X 1 , X 2 , X 3 , and X 4 , are mutated from the residues in the wild type sequence [wherein in the wild-type sequence, X 1 is arginine (R), X 2 is glutamine (Q), X 3 is tyrosine (Y), and X 4 is arginine (R)] to glycine (G), alanine (A) or valine (V);

provided that where only two residues are mutated, X 1 and X 2 are not both mutated to A.

2. The method of claim 1 wherein the M-Topoisomerase charged with the desired nucleotide or oligomer is produced by reacting M-Topoisomerase with an oligonucleotide comprising a recognition sequence of 5′-(C/T)CCTT-3′ in an aqueous medium having NaCl concentration of less than 200 mM.

3. The method of claim 1 , wherein the M-Topoisomerase comprises SEQ ID NO: 4.

4. A method for synthesizing DNA comprising reacting a donor DNA comprising a M-Topoisomerase bound to the 3′ phosphate of a terminal 5′-CCCTT-3′ sequence of the donor DNA with an acceptor DNA, so that the donor and acceptor DNA are ligated thereby and the M-topoisomerase is released, then dephosphorylating the 5′ terminal of the ligated DNA using a phosphatase, reacting the dephosphorylated DNA with a further donor DNA sequence comprising a M-Topoisomerase bound to the 3′ phosphate of a terminal 5′-CCCTT-3′ sequence, to obtain a further ligated DNA, and repeating until the desired sequence is obtained; wherein the M-Topoisomerase exhibits weakened covalent binding to the CCCTT recognition site in the presence of NaCl concentrations of greater than 200 mM, relative to a wild-type topoisomerase, and wherein the reaction takes place in a medium wherein the NaCl concentration is greater than 200 mM, wherein the M-Topoisomerase is a topoisomerase comprising the following sequence:

SEQ ID NO: 3

RALFYKDGKLFTDNNFLNPVSDDNPAYEVLQHVKIPTHLTDVVVYEQTWEEALTRLIFV GSDSKGX 1 RX 2 X 3 FYGKMHVQNX 4 NAKRDRIFVRVYNVMKRINCFINKNIKKSSTDSNYQ LAVFMLMETMFFIRFGKMKYLKENETVGLLTLKNKHIEISPDEIVIKFVGKDKVSHEFVV HKSNRLYKPLLKLTDDSSPEEFLFNKLSERKVYECIKQFGIRIKDLRTYGVNYTFLYNFW TNVKSISPLPSPKKLIALTIKQTAEVVGHTPSISKRAYMATTILEMVKDKNFLDVVSKTTF DEFLSIVVDHVKSSTDG

wherein at least two of X 1 , and X 4 , are mutated from the residues in the wild type sequence [wherein in the wild-type sequence, X 1 is arginine (R), X 2 is glutamine (Q), X 3 is tyrosine (Y), and X 4 is arginine (R)] to glycine (G), alanine (A) or valine (V);

provided that where only two residues are mutated, X 1 and X 2 are not both mutated to A.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2022
From: PREDKI, PAUL F.; BOEHME, STEFEN
To: IRIDIA, INC.
Reel/Frame 059975/0049 →
Continuity (1)
Provisional Application 62842333 · May 2, 2019
Cited By (1)
US 12,338,470